(7) has demonstrated a positive correlation between high CD8+TILs levels and prolonged OS in HER2-positive BC patients, suggesting that CD8+ T cells-mediated cytotoxic immune responses may predict better clinical outcomes after standard chemotherapy and HER2 blockade treatment. The gene discussed is ERBB2; the disease is breast cancer.